Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Panel disputes Vytorin-cancer link

This article was originally published in The Tan Sheet

Executive Summary

The Clinical Trials Service Unit at the University of Oxford, U.K., says data "do not provide credible evidence" that the Vytorin lipid-lowering combination product increases cancer risk. The independent oncology review panel says July 21 a previous trial suggesting the cancer link should not derail Vytorin's promise as a cardiovascular therapy. However, the panel said no significant difference appeared between patients taking Vytorin and placebo on the combined primary endpoint of major cardiovascular events caused by either atherosclerosis or aortic valve disease, or by aortic stenosis alone. This finding follows concerns raised about the general efficacy of the combination of Schering-Plough's Zetia (ezetimibe) and Merck's Zocor (simvastatin) by unfavorable results from the companies' Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial. The ENHANCE data, released in January two years after the study's conclusion, showed Vytorin had no significant edge over simvastatin alone in preventing formation of arterial plaque (1"The Tan Sheet" Jan. 21, 2008, p. 12)...

You may also be interested in...



ENHANCE Results Do Little To Enhance Merck’s Statin Product Outlook

The Merck/Schering-Plough combination cholesterol therapy Vytorin has failed to demonstrate significant benefit over simvastatin alone in preventing formation of arterial plaque in the ENHANCE trial

New Accelerated Approval Withdrawal Process More Streamlined, Marks Says

OCE Director Richard Pazdur was less sanguine, however, noting that while the Pepaxto withdrawal may have been faster than others, it still required more than 60 meetings to complete.

Singulair’s Psychiatric AE Risks Still A Problem, But US FDA Has Limited Mitigation Options Remaining

Stakeholders suggested a ‘Dear Healthcare Provider’ letter or speaking about the risks to professional societies to emphasize the psychiatric adverse events that prompted a boxed warning for the now-generic asthma drug montelukast. The NY Attorney General is adding more pressure.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel